“In the first quarter, our team showcased its clinical development capabilities, initiating FORTIFY, the Phase 1b trial of PLN-101095, ahead of schedule and dosing the first patient in April,” said Bernard Coulie, President and Chief Executive Officer of Pliant. “We were excited to highlight encouraging recent data from the Phase 1a trial of PLN-101095 at AACR showing deepening responses and increasing time on treatment. The team continues to make progress on pipeline programs emerging from Pliant’s proprietary integrin platform while evaluating opportunities to expand our clinical-stage pipeline.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- PLRX Earnings this Week: How Will it Perform?
- Pliant Therapeutics doses first participant in FORTIFY expansion trial
- Pliant announces presentation of updated data from Phase 1 trial of PLN-101095
- Pliant Therapeutics Announces Board Retirements and Option Repricing
- Pliant Therapeutics Launches New $50 Million ATM Program